Cargando…

Progestin Resistance and Corresponding Management of Abnormal Endometrial Hyperplasia and Endometrial Carcinoma

SIMPLE SUMMARY: Patients with endometrial hyperplasia (EH) and endometrial cancer (EC) often fail conservative treatment due to progestin resistance. This article reviews the therapeutic role of progestin in EH and EC as well as the mechanisms of progestin resistance, and systematically expounds pot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lv, Mu, Chen, Peiqin, Bai, Mingzhu, Huang, Yan, Li, Linxia, Feng, Youji, Liao, Hong, Zheng, Wenxin, Chen, Xiaojun, Zhang, Zhenbo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776943/ https://www.ncbi.nlm.nih.gov/pubmed/36551694 http://dx.doi.org/10.3390/cancers14246210

Ejemplares similares

Progestin Intrauterine Devices and Metformin: Endometrial Hyperplasia and Early Stage Endometrial Cancer Medical Management
por: Nwanodi, Oroma
Publicado: (2017)

Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis
por: Shao, Fengping, et al.
Publicado: (2023)

Identification of Genes and Pathways Differentially Expressed in Progestin Responsive Endometrial Cancer and Hyperplasia
por: Gertz, Jay, et al.
Publicado: (2021)

Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway
por: Wang, Yiying, et al.
Publicado: (2016)

Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients
por: Mitsuhashi, Akira, et al.
Publicado: (2019)

Identification of potential models for predicting progestin insensitivity in patients with endometrial atypical hyperplasia and endometrioid endometrial cancer based on ATAC-Seq and RNA-Seq integrated analysis
por: Hu, Jia-Li, et al.
Publicado: (2022)

Ovarian stimulation in IVF couples with severe male factor infertility: GnRH antagonist versus long GnRH agonist
por: Lv, Mu, et al.
Publicado: (2022)

Characteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment
por: Zhou, Shuang, et al.
Publicado: (2021)

NrCAM secreted by endometrial stromal cells enhances the progestin sensitivity of endometrial cancer cells through epigenetic modulation of PRB
por: Cheng, Yali, et al.
Publicado: (2022)

Clinical implications of morular metaplasia in fertility-preserving treatment for atypical endometrial hyperplasia and early endometrial carcinoma patients
por: Wu, Pengfei, et al.
Publicado: (2022)

Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia
por: Shan, Weiwei, et al.
Publicado: (2014)

Efficacy of Oral Medications or Intrauterine Device-Delivered Progestin in Patients with Endometrial Hyperplasia with or without Atypia: A Network Meta-Analysis
por: Zhang, Yu-Fei, et al.
Publicado: (2023)

Prominent decidualization following progestin treatment for endometrial hyperplasia and carcinoma as a mimic of large residual tumor: A cautionary tale
por: Hu, Yang, et al.
Publicado: (2021)

Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group study
por: Kim, Mi Kyoung, et al.
Publicado: (2020)

Fertility-preserving treatment in complex atypical hyperplasia and early endometrial cancer in young women with oral progestin: Is it effective?
por: Baek, Ji Sun, et al.
Publicado: (2016)

RNA‐seq and ATAC‐seq analysis of CD163 (+) macrophage‐induced progestin‐insensitive endometrial cancer cells
por: Wang, Lulu, et al.
Publicado: (2022)

PTEN Sequence Analysis in Endometrial Hyperplasia and Endometrial Carcinoma in Slovak Women
por: Gbelcová, H., et al.
Publicado: (2015)

HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia
por: Ørbo, Anne, et al.
Publicado: (2016)

HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia
por: Ørbo, Anne, et al.
Publicado: (2016)

Response to comment on: Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group study
Publicado: (2020)

Letter to editor in response to: Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group study
Publicado: (2020)

Thyroid Hormone Receptor β Knockdown Reduces Suppression of Progestins by Activating the mTOR Pathway in Endometrial Cancer Cells
por: Ren, Bingtao, et al.
Publicado: (2022)

Endometrial hyperplasia as a risk factor of endometrial cancer
por: Nees, Lisa K., et al.
Publicado: (2022)

Progestins Related to Progesterone and Testosterone Elicit Divergent Human Endometrial Transcriptomes and Biofunctions
por: Houshdaran, Sahar, et al.
Publicado: (2020)

Rate of Significant Endometrial Pathology in Women at Low Risk for Endometrial Hyperplasia or Cancer Presenting with Abnormal Uterine Bleeding
por: Sattanakho, Pattarawadee, et al.
Publicado: (2020)

Association of the Apolipoprotein E 2 Allele with Concurrent Occurrence of Endometrial Hyperplasia and Endometrial Carcinoma
por: Ivanova, Tatiana I., et al.
Publicado: (2015)

Should we abandon hormonal therapy in endometrial cancer? Outcomes of recurrent and metastatic endometrial cancer treated with systemic progestins
por: Kulkarni, A., et al.
Publicado: (2023)

FKBP51 decreases cell proliferation and increases progestin sensitivity of human endometrial adenocarcinomas by inhibiting Akt
por: Dong, Jing, et al.
Publicado: (2017)

Risk factor analysis of coexisting endometrial carcinoma in patients with endometrial hyperplasia: a retrospective observational study of Taiwanese Gynecologic Oncology Group
por: Chen, Yu-Li, et al.
Publicado: (2013)

Menopausal Status Combined with Serum CA125 Level Significantly Predicted Concurrent Endometrial Cancer in Women Diagnosed with Atypical Endometrial Hyperplasia before Surgery †
por: Lou, Yaochen, et al.
Publicado: (2021)

Dual progestin therapy for fertility-sparing treatment of grade 2 endometrial adenocarcinoma
por: Newtson, A.M., et al.
Publicado: (2017)

Chlorpromazine Sensitizes Progestin-Resistant Endometrial Cancer Cells to MPA by Upregulating PRB
por: Cui, Yunxia, et al.
Publicado: (2021)

Risk factors of endometrial cancer in patients with endometrial hyperplasia: implication for clinical treatments
por: Zhao, Jie, et al.
Publicado: (2021)

Pregnancy outcomes of women who received conservative therapy for endometrial carcinoma or atypical endometrial hyperplasia
por: Matsuzaki, Toshiya, et al.
Publicado: (2018)

Endometrial Metaplastic/Reactive Changes Coexistent with Endometrial Hyperplasia and Carcinoma: A Morphological and Immunohistochemical Study
por: Travaglino, Antonio, et al.
Publicado: (2021)

Fertility-Sparing Treatment for Endometrial Cancer or Atypical Endometrial Hyperplasia Patients With Obesity
por: Chen, Junyu, et al.
Publicado: (2022)

Stigmasterol sensitizes endometrial cancer cells to chemotherapy by repressing Nrf2 signal pathway
por: Liao, Hong, et al.
Publicado: (2020)

Combined estrogen-progestin pill is a safe and effective option for endometrial hyperplasia without atypia: a three-year single center experience
por: Wang, Yang, et al.
Publicado: (2019)

Prediction of Endometrial Hyperplasia and Cancer among Premenopausal Women with Abnormal Uterine Bleeding
por: Giannella, Luca, et al.
Publicado: (2019)

Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer
por: Holland, C M, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_eh36rn71uq951tmv20b92nnch3